Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9625882 | 0.78 | LMNA (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL569903 | 0.77 | HSP90AA1 (0.38) | HSP90AA1 | |
| SCHEMBL1118141 | 0.74 | LMNA (0.43) | LMNASMN1; SMN2 | |
| SCHEMBL2333580 | 0.72 | HSP90AA1 (0.41) | HSP90AA1 | |
| SCHEMBL21247994 | 0.72 | HSP90AA1 (0.41) | HSP90AA1 | |
| SCHEMBL7558103 | 0.72 | HSP90AA1 (0.35) | SMN1; SMN2HSP90AA1 | |
| Pyridine SCHEMBL28431692 | 0.70 | TDP1 (0.41) | LMNASMN1; SMN2 | |
| SCHEMBL5252407 | 0.70 | LMNA (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL765855 | 0.70 | APLNR (0.41) | LMNASMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL8036769 | 0.70 | HSP90AA1 (0.33) | HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605163-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | JOLIDON SYNESE | 2008-05-22 | — | — | US | disclosed |
| US-7319099-B2 | Such as 1-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl benzoyl)-piperazin-1-yl]-phenyl}-ethanone for treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia, attention deficit disorders, or Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050209241-A1 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-22 | — | — | US | disclosed |
| EP-0665255-B1 | N-Methylol derivates of polycondensates based on ureas and polyamines | DYSTAR TEXTILFARBEN GMBH & CO (DE) | 2001-05-30 | — | — | EP | disclosed |
| US-5569724-A | AGENTS FOR IMPROVING WETFASTNESS OF DYEINGS ON CELLULOSE AND CELLULOSE BLEND FABRICS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-10-29 | — | — | US | disclosed |
| EP-0665255-A2 | N-Methylol derivates of polycondensates based on ureas and polyamines | BAYER AG (DE) | 1995-08-02 | — | — | EP | disclosed |
| WO-1991013065-A1 | 6-ARYL-2-SUBSTITUTED BENZOIC ACID HERBICIDES | FMC CORPORATION (US) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209241-A1 | Benzoyl-piperazine derivatives | SLC1A2, SLC18A2, SLC6A7 | LMNA 4719/4885SMN1; SMN2 1268/4885HSP90AA1 763/4885 |
| US-20080119486-A1 | BENZOYL-PIPERAZINE DERIVATIVES | SLC1A2, SLC18A2, SLC6A7 | LMNA 4719/4885SMN1; SMN2 1268/4885HSP90AA1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.